Hualan Biological EngineeringInc - Asset Resilience Ratio
Hualan Biological EngineeringInc (002007) has an Asset Resilience Ratio of 14.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Hualan Biological EngineeringInc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Hualan Biological EngineeringInc's Asset Resilience Ratio has changed over time. See how leveraged is Hualan Biological EngineeringInc's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hualan Biological EngineeringInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002007 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.39 Billion | 14.68% |
| Total Liquid Assets | CN¥2.39 Billion | 14.68% |
Asset Resilience Insights
- Moderate Liquidity: Hualan Biological EngineeringInc has 14.68% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Hualan Biological EngineeringInc Industry Peers by Asset Resilience Ratio
Compare Hualan Biological EngineeringInc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Hualan Biological EngineeringInc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Hualan Biological EngineeringInc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.58% | CN¥1.89 Billion ≈ $276.28 Million |
CN¥16.31 Billion ≈ $2.39 Billion |
-1.55pp |
| 2023-12-31 | 13.13% | CN¥2.11 Billion ≈ $309.47 Million |
CN¥16.11 Billion ≈ $2.36 Billion |
-2.94pp |
| 2022-12-31 | 16.07% | CN¥2.37 Billion ≈ $346.71 Million |
CN¥14.74 Billion ≈ $2.16 Billion |
-6.97pp |
| 2021-12-31 | 23.05% | CN¥2.66 Billion ≈ $389.10 Million |
CN¥11.54 Billion ≈ $1.69 Billion |
-6.70pp |
| 2020-12-31 | 29.75% | CN¥2.99 Billion ≈ $436.95 Million |
CN¥10.04 Billion ≈ $1.47 Billion |
-0.68pp |
| 2019-12-31 | 30.43% | CN¥2.31 Billion ≈ $337.65 Million |
CN¥7.58 Billion ≈ $1.11 Billion |
-0.88pp |
| 2018-12-31 | 31.31% | CN¥2.03 Billion ≈ $297.48 Million |
CN¥6.49 Billion ≈ $950.14 Million |
+6.80pp |
| 2017-12-31 | 24.51% | CN¥1.28 Billion ≈ $187.19 Million |
CN¥5.22 Billion ≈ $763.75 Million |
-3.52pp |
| 2016-12-31 | 28.03% | CN¥1.30 Billion ≈ $190.76 Million |
CN¥4.65 Billion ≈ $680.51 Million |
+2.17pp |
| 2015-12-31 | 25.86% | CN¥1.04 Billion ≈ $152.16 Million |
CN¥4.02 Billion ≈ $588.47 Million |
-0.67pp |
| 2014-12-31 | 26.53% | CN¥1.00 Billion ≈ $146.33 Million |
CN¥3.77 Billion ≈ $551.62 Million |
-- |
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more